> top > projects > sentences > docs > PubMed:26028668 > annotations
sentences Home  

PubMed:26028668 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-114 Sentence denotes High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
T1 0-114 Sentence denotes High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
TextSentencer_T2 115-265 Sentence denotes Mesothelin is a cell surface glycoprotein which is highly expressed in several epithelial cancers and may have a role in cell adhesion and metastases.
T2 115-265 Sentence denotes Mesothelin is a cell surface glycoprotein which is highly expressed in several epithelial cancers and may have a role in cell adhesion and metastases.
TextSentencer_T3 266-413 Sentence denotes In this study, we used prospectively obtained clinical and pathological data to characterize mesothelin expression in advanced lung adenocarcinoma.
T3 266-413 Sentence denotes In this study, we used prospectively obtained clinical and pathological data to characterize mesothelin expression in advanced lung adenocarcinoma.
TextSentencer_T4 414-605 Sentence denotes Tissue was obtained from patients who underwent molecular profiling of potentially actionable genes on a trial of molecular profiling and targeted therapies in advanced thoracic malignancies.
T4 414-605 Sentence denotes Tissue was obtained from patients who underwent molecular profiling of potentially actionable genes on a trial of molecular profiling and targeted therapies in advanced thoracic malignancies.
TextSentencer_T5 606-742 Sentence denotes We immunohistochemically evaluated the intensity, and the percentage of cells expressing mesothelin in 93 advanced lung adenocarcinomas.
T5 606-742 Sentence denotes We immunohistochemically evaluated the intensity, and the percentage of cells expressing mesothelin in 93 advanced lung adenocarcinomas.
TextSentencer_T6 743-801 Sentence denotes The evaluation was blinded for molecular data and outcome.
T6 743-801 Sentence denotes The evaluation was blinded for molecular data and outcome.
TextSentencer_T7 802-981 Sentence denotes Mutations of EGFR, KRAS, BRAF, AKT1, PIK3CA and HER2 were assessed by pyrosequencing; HER2 amplification and ALK translocation were assessed by fluorescence in situ hybridization.
T7 802-981 Sentence denotes Mutations of EGFR, KRAS, BRAF, AKT1, PIK3CA and HER2 were assessed by pyrosequencing; HER2 amplification and ALK translocation were assessed by fluorescence in situ hybridization.
TextSentencer_T8 982-1173 Sentence denotes 53% of advanced lung adenocarcinomas expressed mesothelin to some degree; high mesothelin expression, defined as mesothelin positivity in more than 25% of cells, was found in 24% of patients.
T8 982-1173 Sentence denotes 53% of advanced lung adenocarcinomas expressed mesothelin to some degree; high mesothelin expression, defined as mesothelin positivity in more than 25% of cells, was found in 24% of patients.
TextSentencer_T9 1174-1287 Sentence denotes High mesothelin expression was associated with inferior survival (median 18.2 months vs. 32.9 months; P = 0.014).
T9 1174-1287 Sentence denotes High mesothelin expression was associated with inferior survival (median 18.2 months vs. 32.9 months; P = 0.014).
TextSentencer_T10 1288-1400 Sentence denotes High mesothelin expression was strongly associated with mutant KRAS (P < 0.0001) and wild-type EGFR (P = 0.002).
T10 1288-1400 Sentence denotes High mesothelin expression was strongly associated with mutant KRAS (P < 0.0001) and wild-type EGFR (P = 0.002).
TextSentencer_T11 1401-1555 Sentence denotes Our results provide strong rationale to explore anti-mesothelin targeted therapies in advanced lung adenocarcinoma especially in the KRAS-mutant subgroup.
T11 1401-1555 Sentence denotes Our results provide strong rationale to explore anti-mesothelin targeted therapies in advanced lung adenocarcinoma especially in the KRAS-mutant subgroup.